Market By Type, Technology, Age Group, Delivery Mode And Geography | Forecast 2019-2028
According to an analysis by Triton Market Research, the influenza vaccines market in North America is likely to augment at a CAGR of 6.06% over the forthcoming period between 2019 and 2028.
Report scope can be customized per your requirements. Request For Customization
The countries evaluated in the
North American influenza vaccines market are:
• Canada
• The United States
In the United States, hospitalization rates associated with laboratory-confirmed influenza remain to be moderate, with hospitalization rates for schoolgoing children aged 5-17 years higher than any other recent regular season. Hence, the above factors are contributing to the increased growth of the influenza vaccines market in the country.
According to infectious disease experts, a type of influenza B has begun circulating at the end of the year 2019, spreading at the same rate as influenza A. Most of the time, influenza B circulates too late in the season. The changing scenario has kept experts on alert because such type of influenza is associated with a higher risk of hospitalizations and deaths, particularly among children.
FluWatch report, which was released in Jan 2020, states that the growing presence of influenza B is responsible for high cases of pediatric illnesses and hospitalizations. About 258 pediatric hospitalizations associated with influenza were reported during the period between December 15 and January 4. The rising prevalence of influenza is likely to push the demand for the influenza vaccines market in the US. This will contribute to the growth of the studied market in the forecasted period.
Pfizer is a biopharmaceutical company involved in the development and manufacturing of human & veterinary medicines and healthcare products. The company has three major business operational segments, Pfizer Biopharmaceuticals Group, Consumer Healthcare and Upjohn. It provides different products, including human & animal biologic medicines or vaccines, consumer healthcare products and nutritional products. Enzira is an influenza vaccine provided by the company. It is headquartered in New York, the US.
Market By Type, Application, E ..
VIEW REPORT
Market By Device Type, Therape ..
VIEW REPORT
Market By Type, Application, T ..
VIEW REPORT
Market By Technology, Applicat ..
VIEW REPORT
Market By Application, Type, E ..
VIEW REPORT
Market by Therapeutics, Diagno ..
VIEW REPORT
Market by Type, Application, E ..
VIEW REPORT1. NORTH AMERICA INFLUENZA VACCINES MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. MARKET DEFINITION
2.2. KEY INSIGHTS
2.2.1. QUADRIVALENT IS THE DOMINANT TYPE OF INFLUENZA VACCINE
2.2.2. INJECTION IS FASTEST-GROWING DELIVERY MODE
2.2.3. CELL-BASED TECHNOLOGY IS RAPIDLY GROWING TECHNOLOGY IN THE MARKET
2.2.4. ADULT AGE GROUP IS MAJORLY CONTRIBUTING IN THE MARKET
2.3. PORTER’S FIVE FORCE ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE
2.3.3. BARGAINING POWER OF SUPPLIERS
2.3.4. BARGAINING POWER OF BUYERS
2.3.5. INTENSITY OF COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR SCORECARD
2.6. MARKET DRIVERS
2.6.1. ADVANCEMENT IN TECHNOLOGY
2.6.2. INITIATIVES TAKEN UP BY THE GOVERNMENT
2.7. MARKET RESTRAINTS
2.7.1. HIGH COST OF DEVELOPMENT
2.8. MARKET OPPORTUNITIES
2.8.1. GROWTH IN THE CASES OF INFLUENZA
2.9. MARKET CHALLENGES
2.9.1. COMPLEX DEVELOPMENT PROCESS
3. INFLUENZA VACCINES MARKET OUTLOOK - BY TYPE
3.1. QUADRIVALENT VACCINE
3.2. TRIVALENT VACCINE
4. INFLUENZA VACCINES MARKET OUTLOOK - BY TECHNOLOGY
4.1. EGG-BASED TECHNOLOGY
4.2. CELL-BASED TECHNOLOGY
5. INFLUENZA VACCINES MARKET OUTLOOK - BY AGE GROUP
5.1. PEDIATRIC AGE GROUP
5.2. ADULT AGE GROUP
6. INFLUENZA VACCINES MARKET OUTLOOK - BY DELIVERY MODE
6.1. INJECTION
6.2. NASAL SPRAY
7. INFLUENZA VACCINES MARKET – NORTH AMERICA
7.1. UNITED STATES
7.2. CANADA
8. COMPETITIVE LANDSCAPE
8.1. MERCK SHARP & DOHME CORP
8.2. NOVARTIS AG
8.3. PFIZER INC
8.4. SANOFI
8.5. BIODIEM
8.6. EMERGENT BIOSOLUTIONS INC
8.7. F. HOFFMANN-LA ROCHE LTD
8.8. GLAXOSMITHKLINE PLC
8.9. ABBOTT
8.10. CSL LIMITED
9. RESEARCH METHODOLOGY & SCOPE
9.1. RESEARCH SCOPE & DELIVERABLES
9.1.1. OBJECTIVES OF STUDY
9.1.2. SCOPE OF STUDY
9.2. SOURCES OF DATA
9.2.1. PRIMARY DATA SOURCES
9.2.2. SECONDARY DATA SOURCES
9.3. RESEARCH METHODOLOGY
9.3.1. EVALUATION OF PROPOSED MARKET
9.3.2. IDENTIFICATION OF DATA SOURCES
9.3.3. ASSESSMENT OF MARKET DETERMINANTS
9.3.4. DATA COLLECTION
9.3.5. DATA VALIDATION & ANALYSIS
TABLE 1: NORTH AMERICA INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
TABLE 2: VENDOR SCORECARD
TABLE 3: NORTH AMERICA INFLUENZA VACCINES MARKET, BY TYPE, 2019-2028 (IN $ MILLION)
TABLE 4: NORTH AMERICA INFLUENZA VACCINES MARKET, BY TECHNOLOGY, 2019-2028 (IN $ MILLION)
TABLE 5: NORTH AMERICA INFLUENZA VACCINES MARKET, BY AGE GROUP, 2019-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA INFLUENZA VACCINES MARKET, BY DELIVERY MODE, 2019-2028 (IN $ MILLION)
TABLE 7: NORTH AMERICA INFLUENZA VACCINES MARKET, BY COUNTRY, 2019-2028 (IN $ MILLION)
FIGURE 1: NORTH AMERICA INFLUENZA VACCINES MARKET, BY SOURCE, 2019 & 2028 (IN %)
FIGURE 2: NORTH AMERICA QUADRIVALENT INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 3: NORTH AMERICA INJECTION DELIVERY MODEL MARKET, 2019-2028 (IN $ MILLION)
FIGURE 4: NORTH AMERICA CELL-BASED TECHNOLOGY MARKET, 2019-2028 (IN $ MILLION)
FIGURE 5: NORTH AMERICA ADULT AGE GROUP MARKET, 2019-2028 (IN $ MILLION)
FIGURE 6: PORTER’S FIVE FORCE ANALYSIS
FIGURE 7: MARKET ATTRACTIVENESS INDEX
FIGURE 8: NORTH AMERICA INFLUENZA VACCINES MARKET, BY QUADRIVALENT VACCINE, 2019-2028 (IN $ MILLION)
FIGURE 9: NORTH AMERICA INFLUENZA VACCINES MARKET, BY TRIVALENT VACCINES, 2019-2028 (IN $ MILLION)
FIGURE 10: NORTH AMERICA INFLUENZA VACCINES MARKET, BY EGG-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 11: NORTH AMERICA INFLUENZA VACCINES MARKET, BY CELL-BASED TECHNOLOGY, 2019-2028 (IN $ MILLION)
FIGURE 12: NORTH AMERICA INFLUENZA VACCINES MARKET, BY PEDIATRIC AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 13: NORTH AMERICA INFLUENZA VACCINES MARKET, BY ADULT AGE GROUP, 2019-2028 (IN $ MILLION)
FIGURE 14: NORTH AMERICA INFLUENZA VACCINES MARKET, BY INJECTION, 2019-2028 (IN $ MILLION)
FIGURE 15: NORTH AMERICA INFLUENZA VACCINES MARKET, BY NASAL SPRAY, 2019-2028 (IN $ MILLION)
FIGURE 16: NORTH AMERICA INFLUENZA VACCINES MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
FIGURE 17: UNITED STATES INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)
FIGURE 18: CANADA INFLUENZA VACCINES MARKET, 2019-2028 (IN $ MILLION)